MCID: INS002
MIFTS: 59

in Situ Carcinoma

Categories: Cancer diseases, Eye diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for in Situ Carcinoma

MalaCards integrated aliases for in Situ Carcinoma:

Name: in Situ Carcinoma 12 15
Carcinoma in Situ 44 73

Classifications:



External Ids:

Disease Ontology 12 DOID:8719
ICD10 33 D09.9
MeSH 44 D002278
NCIt 50 C2917
SNOMED-CT 68 68956006
UMLS 73 C0007099

Summaries for in Situ Carcinoma

Disease Ontology : 12 A carcinoma that is an early development defined by the absence of invasion of surrounding tissues.

MalaCards based summary : in Situ Carcinoma, also known as carcinoma in situ, is related to comedo carcinoma and lobular neoplasia. An important gene associated with in Situ Carcinoma is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are Gene Expression and Endometrial cancer. The drugs Cervarix and Gardasil have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and cervix, and related phenotypes are cellular and cardiovascular system

Wikipedia : 76 Carcinoma in situ (CIS), also known as in situ neoplasm, is a group of abnormal cells. While they are a... more...

Related Diseases for in Situ Carcinoma

Diseases in the Lip Cancer family:

Pre-Malignant Neoplasm Lip Carcinoma in Situ
in Situ Carcinoma Eye Carcinoma in Situ

Diseases related to in Situ Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 379)
# Related Disease Score Top Affiliating Genes
1 comedo carcinoma 33.4 ERBB2 ESR1
2 lobular neoplasia 33.2 BRCA1 CDH1 ERBB2 ESR1
3 ductal carcinoma in situ 33.1 BRCA1 CDH1 EGFR ERBB2 ESR1 KRT14
4 endometrium carcinoma in situ 33.0 PGR TP53
5 cervix uteri carcinoma in situ 32.1 CDKN2A KRT17 SERPIND1 TP53
6 breast carcinoma in situ 32.1 BRCA1 EGFR ERBB2 ESR1 KRT5 PGR
7 vulva cancer 31.6 CDKN2A EGFR TP53
8 cervical cancer 31.5 CDH1 CDKN2A ERBB2 KRT14 KRT5 TP53
9 uterus carcinoma in situ 31.1 CDKN2A KRT17 SERPIND1 TP53
10 breast ductal carcinoma 30.4 BRCA1 CDH1 EGFR ERBB2 ESR1 PGR
11 breast fibroadenoma 30.3 ERBB2 ESR1 KRT14 PGR
12 bladder cancer 30.1 CDH1 CDKN2A EGFR ERBB2 TP53
13 transitional cell carcinoma 30.0 CDH1 CDKN2A EGFR ERBB2 TP53
14 larynx cancer 30.0 CDKN2A EGFR TP53
15 small cell carcinoma 29.9 CDKN2A EGFR TP53
16 mammary paget's disease 29.9 EGFR ERBB2 ESR1 PGR
17 adenosquamous carcinoma 29.9 EGFR KRT5 TP53
18 endometrial squamous cell carcinoma 29.9 CDKN2A ESR1 PGR
19 pleomorphic adenoma carcinoma 29.9 ERBB2 TP53
20 actinic keratosis 29.9 CDKN2A KRT17 TP53
21 intrahepatic cholangiocarcinoma 29.9 CDH1 EGFR TP53
22 apocrine adenocarcinoma 29.8 ERBB2 ESR1 KRT5 PGR
23 carcinosarcoma 29.8 ERBB2 PGR TP53
24 papillary carcinoma 29.7 CDH1 ERBB2 PGR
25 gallbladder cancer 29.7 CDH1 CDKN2A EGFR ERBB2 TP53
26 breast disease 29.7 BRCA1 CDKN2A ERBB2 ESR1 KRT5 PGR
27 cholangiocarcinoma 29.7 CDH1 EGFR ERBB2 TP53
28 basal cell carcinoma 29.6 CDKN2A KRT14 KRT17 KRT5 TP53
29 squamous cell carcinoma 29.6 CDH1 CDKN2A EGFR ERBB2 TP53
30 adenocarcinoma 29.6 CDH1 CDKN2A EGFR ERBB2 TP53
31 ovarian cancer 1 29.6 BRCA1 CDH1 ERBB2 TP53
32 bilateral breast cancer 29.5 BRCA1 ERBB2 PGR
33 cervical squamous cell carcinoma 29.5 CDH1 CDKN2A TP53
34 female breast cancer 29.4 BRCA1 ERBB2 ESR1 PGR TP53
35 papilloma 29.3 CDKN2A KRT14 KRT5 TP53
36 esophageal cancer 29.3 CDH1 CDKN2A EGFR ERBB2 TP53
37 lynch syndrome 29.3 BRCA1 CDKN2A EGFR TP53
38 gastric adenocarcinoma 29.2 CDH1 CDKN2A EGFR ERBB2 TP53
39 pleomorphic adenoma 29.2 ERBB2 KRT14 TP53
40 pancreatic cancer 29.1 BRCA1 CDH1 CDKN2A EGFR ERBB2 TP53
41 basaloid squamous cell carcinoma 29.0 CDKN2A EGFR KRT14 KRT17 TP53
42 ovarian cancer 28.9 BRCA1 CDH1 EGFR ERBB2 ESR1 PGR
43 breast cancer 28.5 BRCA1 CDH1 EGFR ERBB2 ESR1 KIAA0100
44 breast apocrine carcinoma in situ 12.5
45 oral cavity carcinoma in situ 11.7
46 nasal cavity carcinoma in situ 11.7
47 prostate carcinoma in situ 11.7
48 trachea carcinoma in situ 11.7
49 colon carcinoma in situ 11.7
50 larynx carcinoma in situ 11.7

Graphical network of the top 20 diseases related to in Situ Carcinoma:



Diseases related to in Situ Carcinoma

Symptoms & Phenotypes for in Situ Carcinoma

MGI Mouse Phenotypes related to in Situ Carcinoma:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.47 ANXA8L1 BRCA1 CDH1 CDKN2A EGFR ERBB2
2 cardiovascular system MP:0005385 10.41 AGTR1 BRCA1 CDH1 CDKN2A EGFR ERBB2
3 homeostasis/metabolism MP:0005376 10.4 AGTR1 BRCA1 CDH1 CDKN2A EGFR ERBB2
4 growth/size/body region MP:0005378 10.36 AGTR1 BRCA1 CDH1 CDKN2A EGFR ERBB2
5 immune system MP:0005387 10.36 AGTR1 ANXA8L1 BRCA1 CDH1 CDKN2A EGFR
6 mortality/aging MP:0010768 10.36 AGTR1 BRCA1 CDH1 CDKN2A EGFR ERBB2
7 digestive/alimentary MP:0005381 10.35 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
8 hematopoietic system MP:0005397 10.35 AGTR1 ANXA8L1 BRCA1 CDKN2A EGFR ESR1
9 integument MP:0010771 10.31 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
10 behavior/neurological MP:0005386 10.3 AGTR1 BRCA1 CDKN2A ERBB2 ESR1 ITGB4
11 endocrine/exocrine gland MP:0005379 10.3 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
12 embryo MP:0005380 10.17 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
13 adipose tissue MP:0005375 10.16 AGTR1 BRCA1 EGFR ESR1 KRT14 NR3C1
14 craniofacial MP:0005382 10.13 EGFR ERBB2 ITGB4 KRT14 KRT17 KRT5
15 muscle MP:0005369 10.09 BRCA1 CDKN2A EGFR ERBB2 ESR1 NR3C1
16 neoplasm MP:0002006 10.06 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
17 limbs/digits/tail MP:0005371 10.02 BRCA1 EGFR ERBB2 ESR1 KRT5 PGR
18 no phenotypic analysis MP:0003012 10.02 CDH1 CDKN2A EGFR ESR1 KRT17 KRT5
19 normal MP:0002873 9.92 BRCA1 CDH1 EGFR ERBB2 ESR1 NR3C1
20 renal/urinary system MP:0005367 9.76 AGTR1 BRCA1 EGFR ESR1 ITGB4 NR3C1
21 pigmentation MP:0001186 9.73 BRCA1 CDKN2A EGFR KRT14 KRT17 TP53
22 reproductive system MP:0005389 9.65 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
23 respiratory system MP:0005388 9.28 BRCA1 CDKN2A EGFR ERBB2 ESR1 ITGB4

Drugs & Therapeutics for in Situ Carcinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Cervarix 18 49 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
2
Gardasil 18 49 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
3
Valstar 18 VALRUBICIN Anthra Pharmaceuticals October 1998

Drugs for in Situ Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 407)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
2
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2 114977-28-5 148124
3
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
4
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2 120511-73-1 2187
5
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10540-29-1 2733526
6
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 51-43-4 5816
7
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
8
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 329-65-7 838
9
Toremifene Approved, Investigational Phase 4,Phase 3,Phase 2 89778-26-7 3005573
10
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2 107868-30-4 60198
11
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 112809-51-5 3902
12
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3 21645-51-2
13
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 77-92-9 311
14 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
16 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Mitomycins Phase 4,Phase 3,Phase 2,Not Applicable
24 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
25 Interferon-alpha Phase 4,Phase 3,Phase 1,Phase 2
26 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
28 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
30 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Citrate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Estrogen Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
46 Vasoconstrictor Agents Phase 4,Phase 2
47 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
48 Adrenergic alpha-Agonists Phase 4,Phase 2
49 Adrenergic beta-Agonists Phase 4,Phase 2
50 Anti-Asthmatic Agents Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 749)
# Name Status NCT ID Phase Drugs
1 Can Alternative Treatment Have an Impact on Cervical Dysplasia? Unknown status NCT00842738 Phase 4
2 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Completed NCT01448447 Phase 4
3 Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Completed NCT00742222 Phase 4
4 Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip Completed NCT00868088 Phase 4
5 Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization Completed NCT02368054 Phase 4 Bupivacaine;Adrenaline
6 Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia Completed NCT02199327 Phase 4 Mitomycin C;Interferon Alfa-2b
7 Management of Cervical Intraepithelial Neoplasia Grade 2 Completed NCT00733109 Phase 4
8 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
9 Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease Completed NCT01034358 Phase 4
10 Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery Recruiting NCT02627248 Phase 4 Huaier Granule;Epirubicin;Docetaxel;Cyclophosphamide
11 Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study Recruiting NCT03629886 Phase 4
12 HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions Recruiting NCT03051516 Phase 4
13 FASTER-Tlalpan Study Active, not recruiting NCT03105856 Phase 4
14 HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN) Active, not recruiting NCT02087384 Phase 4 Placebo
15 The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) Active, not recruiting NCT02629510 Phase 4 Tachosil
16 Effectiveness of Cervical Screening in HPV Vaccinated Women Enrolling by invitation NCT02149030 Phase 4
17 Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer Withdrawn NCT03238703 Phase 4 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate;Toremifene Citrate
18 Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
19 Topical Imiquimod for Bowen's Disease of the Head and Neck Unknown status NCT00384124 Phase 2, Phase 3 Imiquimod
20 Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study Unknown status NCT01509781 Phase 3
21 Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator Unknown status NCT00321048 Phase 3
22 Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV) Unknown status NCT01095198 Phase 2, Phase 3
23 Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG) Completed NCT01316874 Phase 2, Phase 3 Valrubicin, 800 mg
24 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
25 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
26 Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer Completed NCT00052637 Phase 3 hexaminolevulinate
27 Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Completed NCT02130323 Phase 2, Phase 3 Imiquimod
28 Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions Completed NCT00262899 Phase 3
29 Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ Completed NCT00438659 Phase 3 mometasone furoate
30 Intraoperative Gamma Camera for Breast Cancer Surgery Completed NCT00757302 Phase 3
31 Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer Completed NCT01442519 Phase 3 electromotive mitomycin
32 Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
33 Biological Therapy in Treating Patients With Bladder Cancer Completed NCT00003779 Phase 3
34 Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer Completed NCT00021255 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Herceptin;Carboplatin
35 Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer Completed NCT00006034 Phase 3 doxorubicin hydrochloride
36 Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer Completed NCT00406068 Phase 2, Phase 3 Mycobacterial cell wall-DNA complex
37 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
38 Study of Docetaxel in Breast Cancer Patients Completed NCT00174707 Phase 3 epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, cyclophosphamide
39 A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting Completed NCT02560584 Phase 3 Hexaminolevulinate hydrochloride
40 Surgery and BCG in Treating Patients With Bladder Cancer Completed NCT00002990 Phase 3
41 Docetaxel in Node Positive Adjuvant Breast Cancer Completed NCT00688740 Phase 3 Docetaxel;5-fluorouracil;Doxorubicin;Cyclophosphamide
42 Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer Completed NCT00374322 Phase 3 lapatinib
43 Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer Completed NCT00038467 Phase 3 Tamoxifen;Exemestane
44 Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial Completed NCT02181101 Phase 3 FEC-DocGemzar adjuvant chemotherapy;FEC-Doc adjuvant chemotherapy;Zoledronic acid i.v. 2 years;Zoledronic acid i.v. 5 years
45 Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer Completed NCT00336791 Phase 3 5-Fluorouracil;Cyclophosphamide;Doxorubicin;Paclitaxel;Epirubicin
46 Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer Completed NCT00003771 Phase 3 norethindrone acetate
47 A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study Completed NCT03355820 Phase 3
48 Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) Completed NCT01131312 Phase 3
49 Efficacy Study of Diathermy Cone Biopsy for the Treatment of Cervical Intraepithelial Lesion Completed NCT00995020 Phase 3
50 Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women Completed NCT00337818 Phase 3

Search NIH Clinical Center for in Situ Carcinoma

Cochrane evidence based reviews: carcinoma in situ

Genetic Tests for in Situ Carcinoma

Anatomical Context for in Situ Carcinoma

MalaCards organs/tissues related to in Situ Carcinoma:

41
Breast, Lymph Node, Cervix, Skin, Testes, Lung, Testis

Publications for in Situ Carcinoma

Articles related to in Situ Carcinoma:

(show top 50) (show all 2111)
# Title Authors Year
1
Comparison of Clinical and Pathologic Characteristics of Ductal Carcinoma in Situ Detected on Mammography versus Ultrasound Only in Asymptomatic Patients. ( 30322671 )
2019
2
Detection of high-grade dysplasia, carcinoma in situ and squamous cell carcinoma in the upper aerodigestive tract: Recommendations for optimal use and interpretation of narrow-band imaging. ( 30222908 )
2019
3
Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ. ( 29955142 )
2018
4
The PPARI^ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ. ( 29350308 )
2018
5
Ameloblastic Carcinoma In Situ: Review of Literature and a Case Presentation in a Pediatric Patient. ( 29715060 )
2018
6
Carcinoma in situ within an area of Barrett esophagus in a dog with megaesophagus. ( 29952726 )
2018
7
Glucocorticoids promote transition of ductal carcinoma in situ to invasive ductal carcinoma by inducing myoepithelial cell apoptosis. ( 29973218 )
2018
8
Oncoplastic breast surgery for the management of ductal carcinoma in situ (DCIS): is it oncologically safe? A retrospective cohort analysis. ( 29759643 )
2018
9
Prediction of Occult Invasive Disease in Ductal Carcinoma in Situ Using Deep Learning Features. ( 29398498 )
2018
10
Magnetic resonance imaging findings of high-grade ductal carcinoma in situ of the male breast: A case report. ( 29977557 )
2018
11
Hospitalization burden associated with malignant neoplasia and in situ carcinoma in vulva and vagina during a 5-year period (2009-2013) in Spain: An epidemiological study. ( 29458181 )
2018
12
Controversies Regarding the Diagnosis and Management of Ductal Carcinoma In Situ. ( 29428007 )
2018
13
Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database. ( 29383628 )
2018
14
The association between post-diagnosis health behaviors and long-term quality of life in survivors of ductal carcinoma in situ: a population-based longitudinal cohort study. ( 29417425 )
2018
15
Development of a Model to Predict Invasiveness in Ductal Carcinoma In Situ Diagnosed by Percutaneous Biopsy-Original Study and Critical Evaluation of the Literature. ( 29798815 )
2018
16
Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in Situ. ( 29632058 )
2018
17
Should patients with ductal carcinoma in situ be treated with adjuvant whole breast radiotherapy after breast conservation surgery? ( 29773535 )
2018
18
Prognostic value of ductal carcinoma in situ component in invasive ductal carcinoma of the breast: a Surveillance, Epidemiology, and End Results database analysis. ( 29593431 )
2018
19
Trends and clinicopathological predictors of axillary evaluation in ductal carcinoma in situ patients treated with breast-conserving therapy. ( 29271113 )
2018
20
Patient Experiences and Clinician Views on the Role of Radiation Therapy for Ductal Carcinoma In Situ. ( 29439886 )
2018
21
Role of Preoperative Variables in Reducing the Rate of Occult Invasive Disease for Women Considering Active Surveillance for Ductal Carcinoma In Situ-Reply. ( 29344613 )
2018
22
A comparison of two models for breast cancer mortality for women with ductal carcinoma in situ: an SEER-based analysis. ( 29445939 )
2018
23
Hypofractionated volumetric modulated arc therapy in ductal carcinoma in situ: toxicity and cosmetic outcome from a prospective series. ( 29322827 )
2018
24
Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. ( 29394917 )
2018
25
Overtreatment in surgery - does it concern also the patients with ductal breast carcinoma in situ. ( 29513252 )
2018
26
Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ. ( 29730730 )
2018
27
Upstaging to invasive ductal carcinoma after mastectomy for ductal carcinoma in situ: predictive factors and role of sentinel lymph node biopsy. ( 29786772 )
2018
28
Development and validation of algorithms to differentiate ductal carcinoma in situ from invasive breast cancer within administrative claims data. ( 29669162 )
2018
29
Role of Preoperative Variables in Reducing the Rate of Occult Invasive Disease for Women Considering Active Surveillance for Ductal Carcinoma In Situ. ( 29344621 )
2018
30
Whole-Exome Sequencing of Sinonasal Small Cell Carcinoma Arising within a Papillary Schneiderian Carcinoma In Situ. ( 29734873 )
2018
31
Factors associated with the increasing trend of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ: Analysis of Surveillance, Epidemiology, and End Results data. ( 29804045 )
2018
32
Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. ( 29398324 )
2018
33
Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery. ( 29709458 )
2018
34
Author's reply for letter to editor: Acute pancreatitis-onset carcinoma in situ of the pancreas with focal fat replacement diagnosed using serial pancreatic juice aspiration cytologic examination (SPACE). ( 29508309 )
2018
35
Educational Case: Bladder Carcinoma In Situ. ( 30140732 )
2018
36
Photodynamic therapy for Bowen's Disease (squamous cell carcinoma in situ) current review and update. ( 30240928 )
2018
37
Claudin-4 Expression Is Associated With Disease-Free Survival in Breast Carcinoma-in-Situ: Mean Follow-up of 8.2 Years. ( 30025999 )
2018
38
Evaluation of survivin immunoexpression in the differentiation of high- and low-grade breast ductal carcinoma in situ. ( 29694611 )
2018
39
A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk. ( 30054280 )
2018
40
Functional Role of microRNAs in the Progression of Breast Ductal Carcinoma in situ. ( 30273605 )
2018
41
Morphologic and Molecular Features of Breast Ductal Carcinoma In Situ. ( 30385094 )
2018
42
Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS). ( 30410060 )
2018
43
Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ. ( 30429518 )
2018
44
Possible predictive role of cancer/testis antigens in breast ductal carcinoma in situ. ( 30546463 )
2018
45
Surgical management of carcinoma in situ at ductal resection margins in patients with extrahepatic cholangiocarcinoma. ( 30238077 )
2018
46
A rare case of squamous cell carcinoma in situ arising in mature cystic teratoma. ( 30255001 )
2018
47
Breast-conserving therapy for primary Ductal Carcinoma in Situ in The Netherlands: A multi-center study and population-based analysis. ( 30118902 )
2018
48
Local recurrence outcomes after breast conserving surgery and adjuvant radiotherapy in ductal carcinoma in situ of the breast and a comparison with ECOG E5194 study. ( 30121548 )
2018
49
Case Report: Ductal Carcinoma in Situ Within A Granulomatous Mastitis. ( 30123886 )
2018
50
Ductal carcinoma in-situ, cystic hypersecretory type presented by recurrent hemorrhagic cyst. ( 30124440 )
2018

Variations for in Situ Carcinoma

Expression for in Situ Carcinoma

Search GEO for disease gene expression data for in Situ Carcinoma.

Pathways for in Situ Carcinoma

Pathways related to in Situ Carcinoma according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.7 BRCA1 CDKN2A EGFR ERBB2 ESR1 NR3C1
2
Show member pathways
12.74 CDH1 CDKN2A EGFR ERBB2 TP53
3 12.63 AGTR1 CDH1 CDKN2A EGFR ERBB2 ESR1
4
Show member pathways
12.54 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
5 12.37 BRCA1 CDKN2A EGFR ERBB2 TP53
6
Show member pathways
12.36 ERBB2 ESR1 NR3C1 PPIA
7 12.15 EGFR ERBB2 ESR1 TP53
8
Show member pathways
12.08 BRCA1 CDKN2A ESR1 NR3C1 PGR
9
Show member pathways
12.07 EGFR ERBB2 ITGB4 TP53
10 11.99 BRCA1 CDH1 EGFR ESR1 TP53
11 11.98 EGFR ERBB2 ITGB4 TP53
12
Show member pathways
11.89 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
13
Show member pathways
11.81 EGFR ERBB2 ESR1 PGR
14
Show member pathways
11.75 EGFR ERBB2 ESR1
15
Show member pathways
11.72 ESR1 NR3C1 PGR
16 11.62 BRCA1 CDKN2A ERBB2 TP53
17 11.61 CDH1 EGFR ERBB2
18 11.56 BRCA1 ERBB2 TP53
19 11.55 EGFR ERBB2 TP53
20 11.5 BRCA1 ERBB2 ITGB4
21 11.47 KRT14 KRT17 KRT5 NR3C1 TP53
22 11.39 CDKN2A EGFR TP53
23 11.22 CDH1 CDKN2A EGFR ERBB2 TP53
24 11.05 CDH1 EGFR ERBB2 ITGB4

GO Terms for in Situ Carcinoma

Cellular components related to in Situ Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.8 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
2 protein-containing complex GO:0032991 9.1 BRCA1 EGFR ESR1 NR3C1 PPIA TP53

Biological processes related to in Situ Carcinoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.95 BRCA1 CDKN2A EGFR ESR1 NR3C1 PGR
2 regulation of apoptotic process GO:0042981 9.8 BRCA1 ESR1 PRDX2 TP53
3 positive regulation of cell growth GO:0030307 9.65 EGFR ERBB2 KRT17
4 positive regulation of transcription, DNA-templated GO:0045893 9.63 BRCA1 CDH1 CDKN2A EGFR ESR1 TP53
5 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.52 BRCA1 TP53
6 replicative senescence GO:0090399 9.51 CDKN2A TP53
7 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.46 ESR1 TP53
8 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.43 EGFR TP53
9 negative regulation of ERBB signaling pathway GO:1901185 9.37 EGFR ERBB2
10 cellular response to indole-3-methanol GO:0071681 9.32 BRCA1 CDH1
11 negative regulation of immature T cell proliferation in thymus GO:0033088 9.26 CDKN2A ERBB2
12 epidermis development GO:0008544 9.26 EGFR KRT14 KRT17 KRT5
13 hemidesmosome assembly GO:0031581 8.8 ITGB4 KRT14 KRT5

Molecular functions related to in Situ Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.8 CDKN2A EGFR ESR1 NR3C1 TP53
2 identical protein binding GO:0042802 9.8 BRCA1 CDH1 EGFR ERBB2 ESR1 PGR
3 protein phosphatase binding GO:0019903 9.63 EGFR ERBB2 TP53
4 enzyme binding GO:0019899 9.55 BRCA1 EGFR ESR1 PGR TP53
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.54 EGFR ERBB2 ESR1
6 steroid hormone receptor activity GO:0003707 9.5 ESR1 NR3C1 PGR
7 nitric-oxide synthase regulator activity GO:0030235 9.43 EGFR ESR1
8 nuclear receptor activity GO:0004879 9.13 ESR1 NR3C1 PGR
9 steroid binding GO:0005496 8.8 ESR1 NR3C1 PGR
10 protein binding GO:0005515 10.38 AGTR1 BRCA1 CDH1 CDKN2A EGFR ERBB2

Sources for in Situ Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....